Last reviewed · How we verify
Jason Lang, M.D., M.P.H. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| commercially available lansoprazole | commercially available lansoprazole | phase 3 | Proton pump inhibitor | H+/K+ ATPase | Gastroenterology |
Therapeutic area mix
- Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AVM Biotechnology Inc · 1 shared drug class
- Bayer · 1 shared drug class
- GBG Forschungs GmbH · 1 shared drug class
- HK inno.N Corporation · 1 shared drug class
- IBSA Institut Biochimique SA · 1 shared drug class
- Jun-Won Chung · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
- Samsung Medical Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Jason Lang, M.D., M.P.H.:
- Jason Lang, M.D., M.P.H. pipeline updates — RSS
- Jason Lang, M.D., M.P.H. pipeline updates — Atom
- Jason Lang, M.D., M.P.H. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Jason Lang, M.D., M.P.H. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jason-lang-m-d-m-p-h. Accessed 2026-05-18.